A Study To Evaluate The Safety And Effectiveness Of ALLO-501A CAR T Cell Therapy In Adults With Relapsed/ Refractory Large B Cell Lymphoma

Overview

About this study

The primary purpose of this study is to assess the safety and effectiveness of ALLO-501A to treat patients with relapsed/refractory large B cell lymphoma (LBCL) to determine the maximum tolerated dose (MTD).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Histologically confirmed relapsed/refractory large B-cell lymphoma with at least one  measurable lesion.
  • At least 2 prior lines of chemotherapy including an anthracycline and an anti-CD20  monoclonal antibody.
  • Prior CD19 therapy allowed with evidence of CD19 positive relapse following any prior CD19-directed therapy, including cell therapies.
  • Eastern Cooperative Oncology Group Performance Status of 0 or 1.
  • Absence of donor (product)-specific anti-HLA antibodies.
  • Adequate hematological, renal, liver, pulmonary, and cardiac functions.

Exclusion Criteria:

  • Current or history of central nervous system (CNS) lymphoma.
  • Clinically significant CNS dysfunction.
  • Current thyroid disorder (including hyperthyroidism) with the exception of hypothyroidism controlled on stable dose of hormone replacement therapy.
  • Prior treatment with any anti-CD52 monoclonal antibody.
  • Active acute or chronic graft versus host disease (GVHD).
  • Patients unwilling to participate in an extended safety monitoring period.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Javier Munoz, M.D., M.B.A.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available
.
CLS-20510895

Mayo Clinic Footer